MetaVia (NASDAQ:MTVA) Upgraded by Wall Street Zen to Hold Rating

Wall Street Zen upgraded shares of MetaVia (NASDAQ:MTVA) from a sell rating to a hold rating in a report issued on Saturday.

MTVA has been the subject of a number of other reports. HC Wainwright cut their target price on MetaVia from $40.00 to $20.00 and set a “buy” rating for the company in a research report on Friday. Weiss Ratings restated a “sell (d-)” rating on shares of MetaVia in a research report on Monday, December 22nd. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, MetaVia presently has an average rating of “Hold” and an average price target of $26.50.

MetaVia Price Performance

Shares of NASDAQ:MTVA opened at $1.22 on Friday. The company has a market capitalization of $2.68 million, a P/E ratio of -0.15 and a beta of 0.33. MetaVia has a 1 year low of $1.21 and a 1 year high of $23.10. The business’s 50 day simple moving average is $1.81 and its 200 day simple moving average is $6.80.

Institutional Investors Weigh In On MetaVia

A hedge fund recently bought a new stake in MetaVia stock. Virtu Financial LLC acquired a new position in shares of MetaVia Inc. (NASDAQ:MTVA) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned about 0.14% of MetaVia as of its most recent SEC filing. 1.37% of the stock is currently owned by institutional investors and hedge funds.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.